Boehringer Ingelheim International Gmbh

Evotec International Gmbh

Andreas Blum

Joerg P Hehn

Armin Heckel

Stefan Peters

Frank Himmelsbach

Dieter Wiedenmayer

Dirk Gottschling

Elke Langkopf

Joerg Kley

Neil Ashweek

Bernd Nosse

Nicole Harriott

Bernhard Schmid

Oliver Hucke

Dieter Wolfgang Hamprecht

Thorsten Lehmann-Lintz

Steffen Breitfelder

Cédrickx Godbout

Bernd Wellenzohn

Neil J Ashweek

Dieter Hamprecht

The invention relates to new pyridinyl sulfonamide derivatives of the formula wherein R, A and n are as defined herein, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof

The invention relates to new heteroaryl derivatives of the formula wherein X is selected from the group consisting of: N and CH; X is selected from the group consisting of: N and CF; (with the proviso that at least one of Xand Xis N), and A is as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them. 

Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors

The invention relates to new benzonitrile derivatives of the formula (I) wherein Rto Rand A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them. 

4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors

The application relates to novel sulfoximine substituted quinazoline derivatives of formula wherein Ar, R, Rand Rare as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

Sulfoximine substituted quinazolines for pharmaceutical compositions

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, Rand Rare as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders. 

The invention relates to new pyridinyl derivatives of the formula wherein Rand A are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Pyridinyl derivatives, pharmaceutical compositions and uses thereof

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, Rand Rare as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

The present invention relates to compounds of general formula (I), wherein R, L, L, (Het)Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR1 19 receptor and modulate its activity. 

N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof

The present invention relates to compounds of general formula I, wherein the group R, R, X, Y and Z are defined as in claim, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Azabenzimidazole derivatives

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, Rand Rare as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

Substituted pyrazines and their use in the treatment of disease

The present invention relates to compounds of general formula I, wherein the groups R, L, L, Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

Growing community of inventors

Warthausen, Germany

Andreas Blum